Isolated and Associated Effects of Physical Exercise and Estrogen Therapy on Climactercs Women

Women's Health Clinical Trial

— TRH01/989-7  

Official title:

Isolated and Associated Effects of Physical Exercise and Estrogen Therapy on Climactercs Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01120665
• Other study ID #: TRH01/989-7
• Status: Completed
• Phase: N/A
• First received: April 28, 2010
• Last updated: June 21, 2012
• Start date: February 2002
• Est. completion date: February 2009

Study information

• Verified date: June 2012
• Source: University of Sao Paulo General Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Brazil: National Health Surveillance Agency
• Study type: Interventional

Clinical Trial Summary

This study will investigate the isolated and the associated effect of estrogen therapy and physical exercise in the function, regulation and cardiovascular risk markers of 60 postmenopausal women, (45 - 60 years old). The volunteers will be randomaized into two groups: estrogen therapy (estradiol valerate 1 mg/day oraly) and placebo. The two groups will be randomaized into two subgroups: exercise group (aerobic trainning,cicle-ergometre, 50 minutes, 3 x week) and sedentary group. At 0, 6 and 12 months the volunteers will be submited to: clinical analise, cardiorespiratory analise (ergoepirometric test), quality of life questionare (Short Form-36 [SF-36]), ambulatory blood pressure monitoring during 24 hours and to 2 experimental sessions where the cardiovascular responses to insulin action (euglicemic/hiperinsulinemic clamp) and to physical and mental stress (microneurography) will be accessed. Besides these, the volunteers of the sedentary group will be submited to an extra session at 6 months of study evaluate the physiological answer to insulin infusion after an acute session of exercise.

Description:

More than an isolated event, menopause is an universal process that produces many physiologic changes, affecting not only the reproductive tissues but other systems of women's body. Post-menopause period is usually accompanied by an increase in climacteric symptoms, which decrease healthy related quality of life. Moreover, many unhealthy changes occur at this period of women's life, increasing the risk for metabolic syndrome development, which might be due, at least in part, to an increase in insulin resistance and compensatory hyperinsulinemia.

Hormone therapy is indicated as the main treatment to reduce or relief the negative effects of menopause. Although many studies have confirmed the possible positive effects of this approach on postmenopausal symptoms, its effects on insulin resistance and other metabolic syndrome factors remain controversial.

On the other hand, it's well known that acute and chronic exercises can provide a wide range of benefits for postmenopausal women's health, including decrease of insulin resistance and symptoms relief.

In clinical practice, many postmenopausal women are using hormone therapy and are instructed to exercise. However, the effects of this association are poorly studied.

Thus, the main goal of this randomized placebo-controlled trial was to evaluate, in healthy, middle age, and hysterectomized postmenopausal women, the single and combined effects of physical exercise and oral estrogen use on blood pressure (BP), heart rate (HR), muscle blood flow, and autonomic function measured at baseline conditions and under hyperinsulinemia stimulus. Moreover, it also investigated the effects of these interventions on symptoms relief and quality of life.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: February 2009
• Est. primary completion date: February 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 45 Years to 60 Years

Eligibility

Inclusion Criteria:

• Hysterectomy women, with or without ovaries, confirmed by transvaginal ultrasound.

• Climacteric women, postmenopausal for at least 1 year, with vasomotor symptoms (Kupperman, 1959) and/or laboratory diagnosis of menopause (high luteinizing hormone [LH] and follicle-stimulating hormone [FSH] and estradiol decreased).

Exclusion Criteria:

• Hypertension or other cardiovascular disease (thromboembolism, heart disease, myocardial infarction, stroke, vascular disorders, coronary insufficiency or venous)

• Osteoporosis.

• Diagnose or suspected breast cancer or ovaries.

• Current illness or a history of severe liver failure, jaundice or severe pruritus pregnancy and liver tumor.

• Endocrine and metabolic diseases as diabetes, thyroid disorders, obesity and dyslipidemia.

• Chronic diseases such as kidney diseases and collagen diseases.

• Women with cervical or vaginal malignancies.

• Hypersensitivity to estradiol valerate.

• Previous use of estrogen-containing implants in the last two years, use of hormone replacement therapy (HRT) orally or transdermally in the last three months or HRT use by injection in the last six months before the study start.

• Limited mobility or other physical problems that contraindicate the physical exercises.

• Women who are engaged in regular physical activity.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Women's Health

Intervention

Drug:
• Estradiol valerate
estradiol valerate, 1 mg/day, orally.

Other:
• Aerobic training
Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes)

Drug:
• Placebo
lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate

Other:
• Control
The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University of Sao Paulo General Hospital	Fundação de Amparo à Pesquisa do Estado de São Paulo

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood pressure	Blood pressure will be measured as often as needed, respecting the interval 1-2 minutes among measurements, until you obtain three consecutive measurements with a difference of less than 5 mmHg by auscultation and oscilometric methods. The verification of calibration of the monitor is often assessed by comparison with the mercury.	six months	Yes
Secondary	hemodynamics mechanisms	Hemodynamics mechanisms will be evaluate by air-occlusion pletismography	six months	Yes
Secondary	autonomics mechanisms	autonomics mechanisms will be evaluated by microneurography methods and heart rate and blood pressure variability	six months	Yes